Anbio Biotechnology is setting its sights on the European market with the debut of the AF-100 C, a revolutionary compact fluorescent immunoassay analyser that promises to transform the realm of point-of-care diagnostics. With a repertoire of over 70 assays, the AF-100 C is tailored to significantly bolster the operational capacity of EU healthcare practitioners, thereby elevating the standard of patient diagnosis and treatment.
Anbio Biotechnology (Anbio), a luminary in the in vitro diagnostics sector on a global scale, is ecstatic to roll out its “Point of Care” product suite across the European Union. This unveiling is a strategic move for Anbio, paving the way for fresh collaborations with EU distributors and medical facilities, and showcasing the company’s pledge to supply the EU with premier diagnostic technologies.
Anbio has grown from its initial role as a purveyor of Covid testing kits to a dynamic innovator and producer of an extensive range of diagnostic tools. “Our mission is to revolutionize diagnostics by offering tailored and accessible solutions, including laboratory, wellness, at-home, and point-of-care diagnostics. We are committed to affordability and continuous innovation in life sciences that serve to advance human heath,” Michael Lau, CEO of Anbio, shared.
High-Tech Analyzer Equips Medics with Over 70 Essential Diagnostics
At the forefront of Anbio’s European initiative is the AF-100 C analyzer, a state-of-the-art, single-channel, mobile, rechargeable compact fluorescent Immunoassay (FIA) analyzer. This formidable device, together with over 70 CE-marked assays for a comprehensive range of analytes including markers for inflammation, diabetes, cancer, hormones, enzymes, and infectious diseases, is expected to drastically reshape the clinical diagnostics field within the EU.
“The Anbio AF-100 C is a game-changer for clinical diagnostics, supplying healthcare providers with a cost-effective, comprehensive, and reliable solution for rapid point-of-care testing,” Lau emphasized. The AF-100 C, though compact, is designed for high throughput, making it ideal for diverse clinical scenarios, from outpatient clinics to intensive care units. Its user-friendly interface and resilient battery, offering up to 8 hours of continuous testing, enable medical staff to deliver exemplary patient care with utmost efficiency and accuracy.
Prompt and Reliable Diagnostics to Elevate Healthcare Service Standards
Anbio’s extensive FIA portfolio, which can produce results swiftly within 3 to 15 minutes, represents a significant breakthrough in diagnostic technology. Equipped with reagents that use RFID chip technology for enhanced accuracy and shelf-stable at room temperature for up to two years, Anbio stands ready to meet the critical needs of the European healthcare system.
As Anbio Biotechnology embarks on its journey in the EU market, it invites distributors and healthcare professionals to delve into its advanced diagnostic offerings. With a dedication to improving patient care through affordable, accurate, and dependable diagnostics, Anbio is eager to establish partnerships with healthcare experts across the European Union.
